Epix Pharmaceuticals reported that Schering of Berlin is not going to exercise its option for Epix's fibrin-binding imaging agent EP-2104R. Under terms of an agreement between the firms, full rights to the product revert to Epix.
The compound is a fibrin-binding agent designed to detect blood clots using MRI. After injection the agent localizes in fibrin, allowing visualization of the clot. Epix said it completed two phase IIa studies earlier this year that evaluated the performance of EP-2104R in 52 patients.
The Cambridge, MA-based firm said that although Schering, which is undergoing a merger with Bayer, had decided not to exercise its option on the agent, it would be pursuing development collaboration with other potential partners.
By AuntMinnie.com staff writers
July 13, 2006
Related Reading
Epix files Vasovist appeal with FDA, July 4, 2006
Astrue resigns from Epix, May 8, 2006
Epix to buy Predix Pharmaceuticals, April 3, 2006
Epix adds VPs, February 23, 2006
Sales fall, losses grow for Epix in ’05, February 16, 2006
Copyright © 2006 AuntMinnie.com
